Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
OMECLAMOX-PAK is a fixed-dose combination oral therapy containing amoxicillin, clarithromycin, and omeprazole used for Helicobacter pylori eradication and related gastric conditions. This triple-therapy regimen combines two antibiotics with a proton pump inhibitor to suppress acid and enhance bacterial susceptibility. It represents a mature, well-established treatment approach for peptic ulcer disease and H. pylori infection.
As LOE approaches, brand teams are likely in defend-and-optimize mode with reduced headcount relative to growth-stage products; marketing focus shifts toward generalist promotion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on OMECLAMOX-PAK offers limited career growth as the product is in LOE-approaching phase with minimal clinical development and declining investment. Roles tend to be maintenance-focused and concentrated in commercial teams managing a mature, commoditizing brand.
Worked on OMECLAMOX-PAK at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.